Vanguard Group’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | $5.97B | Sell |
70,079,435
-283,775
| -0.4% | -$23.3M | 0.09% | 212 |
|
|
2025
Q3 | $5.47B | Buy |
70,363,210
+365,581
| +0.5% | +$28.6M | 0.08% | 231 |
|
|
2025
Q2 | $5.47B | Buy |
69,997,629
+798,801
| +1% | +$59.6M | 0.09% | 213 |
|
|
2025
Q1 | $5.02B | Buy |
69,198,828
+66,792
| +0.1% | +$4.78M | 0.09% | 213 |
|
|
2024
Q4 | $5.12B | Buy |
69,132,036
+6,537,494
| +10% | +$458M | 0.09% | 201 |
|
|
2024
Q3 | $4.13B | Buy |
62,594,542
+9,018,528
| +17% | +$655M | 0.07% | 267 |
|
|
2024
Q2 | $4.95B | Buy |
53,576,014
+611,620
| +1% | +$54.2M | 0.1% | 185 |
|
|
2024
Q1 | $5.06B | Buy |
52,964,394
+600,994
| +1% | +$50.5M | 0.1% | 189 |
|
|
2023
Q4 | $3.99B | Buy |
52,363,400
+729,984
| +1% | +$50.8M | 0.09% | 230 |
|
|
2023
Q3 | $3.58B | Buy |
51,633,416
+325,808
| +0.6% | +$26.2M | 0.09% | 227 |
|
|
2023
Q2 | $4.84B | Sell |
51,307,608
-443,619
| -0.9% | -$38.6M | 0.11% | 155 |
|
|
2023
Q1 | $4.28B | Buy |
51,751,227
+191,836
| +0.4% | +$15.1M | 0.11% | 171 |
|
|
2022
Q4 | $3.85B | Buy |
51,559,391
+648,287
| +1% | +$50M | 0.1% | 193 |
|
|
2022
Q3 | $4.21B | Buy |
50,911,104
+604,269
| +1% | +$58.1M | 0.12% | 155 |
|
|
2022
Q2 | $4.78B | Buy |
50,306,835
+581,969
| +1% | +$60.2M | 0.13% | 135 |
|
|
2022
Q1 | $5.85B | Buy |
49,724,866
+648,217
| +1% | +$72.7M | 0.14% | 121 |
|
|
2021
Q4 | $6.36B | Buy |
49,076,649
+269,987
| +0.6% | +$31.5M | 0.14% | 116 |
|
|
2021
Q3 | $5.53B | Buy |
48,806,662
+497,212
| +1% | +$56.8M | 0.14% | 123 |
|
|
2021
Q2 | $5B | Sell |
48,309,450
-159,126
| -0.3% | -$15M | 0.12% | 139 |
|
|
2021
Q1 | $4.05B | Buy |
48,468,576
+120,891
| +0.3% | +$10.2M | 0.11% | 158 |
|
|
2020
Q4 | $4.41B | Sell |
48,347,685
-493,541
| -1% | -$40.9M | 0.13% | 137 |
|
|
2020
Q3 | $3.9B | Sell |
48,841,226
-587,284
| -1% | -$45.8M | 0.13% | 140 |
|
|
2020
Q2 | $3.42B | Sell |
49,428,510
-602,445
| -1% | -$42.8M | 0.12% | 153 |
|
|
2020
Q1 | $3.15B | Buy |
50,030,955
+1,245,849
| +3% | +$89.8M | 0.13% | 142 |
|
|
2019
Q4 | $3.79B | Buy |
48,785,106
+476,559
| +1% | +$37.2M | 0.13% | 147 |
|
|
2019
Q3 | $3.54B | Buy |
48,308,547
+373,014
| +0.8% | +$26.2M | 0.13% | 150 |
|
|
2019
Q2 | $2.95B | Sell |
47,935,533
-8,679,318
| -15% | -$525M | 0.11% | 180 |
|
|
2019
Q1 | $3.61B | Sell |
56,614,851
-8,955,126
| -14% | -$511M | 0.14% | 130 |
|
|
2018
Q4 | $3.35B | Buy |
65,569,977
+1,115,022
| +2% | +$56.4M | 0.15% | 122 |
|
|
2018
Q3 | $3.74B | Buy |
64,454,955
+75,825
| +0.1% | +$3.71M | 0.15% | 121 |
|
|
2018
Q2 | $3.12B | Buy |
64,379,130
+491,241
| +0.8% | +$22.9M | 0.13% | 139 |
|
|
2018
Q1 | $2.97B | Sell |
63,887,889
-99,108
| -0.2% | -$4.3M | 0.13% | 143 |
|
|
2017
Q4 | $2.4B | Buy |
63,986,997
+829,143
| +1% | +$30.4M | 0.11% | 191 |
|
|
2017
Q3 | $2.3B | Buy |
63,157,854
+912,147
| +1% | +$34.8M | 0.11% | 187 |
|
|
2017
Q2 | $2.45B | Buy |
62,245,707
+1,220,703
| +2% | +$44.6M | 0.12% | 163 |
|
|
2017
Q1 | $1.91B | Buy |
61,025,004
+1,517,175
| +3% | +$47.5M | 0.1% | 208 |
|
|
2016
Q4 | $1.86B | Buy |
59,507,829
+1,682,010
| +3% | +$54.5M | 0.1% | 197 |
|
|
2016
Q3 | $2.32B | Buy |
57,825,819
+1,437,267
| +3% | +$54.1M | 0.14% | 144 |
|
|
2016
Q2 | $1.87B | Buy |
56,388,552
+403,296
| +0.7% | +$13.8M | 0.12% | 179 |
|
|
2016
Q1 | $1.65B | Buy |
55,985,256
+1,036,965
| +2% | +$28.6M | 0.11% | 194 |
|
|
2015
Q4 | $1.45B | Buy |
54,948,291
+754,707
| +1% | +$19.6M | 0.1% | 212 |
|
|
2015
Q3 | $1.28B | Sell |
54,193,584
-1,913,004
| -3% | -$46.2M | 0.09% | 229 |
|
|
2015
Q2 | $1.33B | Buy |
56,106,588
+1,304,694
| +2% | +$29.4M | 0.09% | 226 |
|
|
2015
Q1 | $1.3B | Buy |
54,801,894
+2,811,384
| +5% | +$63.1M | 0.09% | 243 |
|
|
2014
Q4 | $1.1B | Buy |
51,990,510
+1,643,310
| +3% | +$33M | 0.08% | 271 |
|
|
2014
Q3 | $857M | Buy |
50,347,200
+5,781,162
| +13% | +$91.3M | 0.07% | 321 |
|
|
2014
Q2 | $638M | Sell |
44,566,038
-154,374
| -0.3% | -$2.09M | 0.05% | 429 |
|
|
2014
Q1 | $553M | Buy |
44,720,412
+551,778
| +1% | +$6.37M | 0.05% | 453 |
|
|
2013
Q4 | $484M | Sell |
44,168,634
-83,196
| -0.2% | -$938K | 0.04% | 486 |
|
|
2013
Q3 | $514M | Sell |
44,251,830
-283,686
| -0.6% | -$3.32M | 0.05% | 428 |
|
|
2013
Q2 | $499M | Buy |
+44,535,516
| New | +$527M | 0.05% | 410 |
|
Other funds holding EW
Vanguard Group's EW Position: Q4 2025 in Review
Vanguard Group reduced its Edwards Lifesciences (EW) stake by 0.4% in Q4 2025, selling an estimated $23.3M and leaving 70,079,435 shares worth $5.97B. The position accounts for 0.09% of the portfolio, ranked #212.
Vanguard Group first reported a position in EW in Q2 2013 and has held it in 51 quarters since. The position peaked at $6.36B in Q4 2021. 1,313 funds tracked by Wall St. Rank hold EW as of Q4 2025.
- Vanguard Group held 70,079,435 shares of Edwards Lifesciences worth $5.97B as of Q4 2025.
- Vanguard Group sold 283,775 Edwards Lifesciences shares in Q4 2025, an estimated $23.3M.
- Edwards Lifesciences made up 0.09% of Vanguard Group's portfolio in Q4 2025, its #212 holding.
- Vanguard Group first reported a position in Edwards Lifesciences in Q2 2013 and has held it in 51 quarters since.
- Vanguard Group's Edwards Lifesciences position peaked at $6.36B in Q4 2021.
- 1,313 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q4 2025.
Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.